BRIOPRYME BIOLOGICS, INC.

Medtech · Private

Decellularized porcine placenta extracellular matrix (DCM) hydrogel device delivered as sterile powder enema for radiation-induced proctitis treatment

Grants
$400K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · A decellularized porcine placenta matrix hydrogel for management of radiation-induced proctitis$400,000
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
666ACTIV SITTING, INC.——
667CHISQUARE BIOIMAGING, LLC——
668STAR VOLTAIC LLC——
669BRIOPRYME BIOLOGICS, INC.——
670STEMORA INC.——
671XCELLASSAY, INC.——
672KINIMMUNE, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Preparation And Use Of Tissue Matrix Derived Powderapplication
  • Preparation And Use Of Tissue Matrix Derived Powderapplication
  • Preparation And Use Of Therapeutic Hydrogelsapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.